Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
25 Julio 2023 - 3:01PM
Business Wire
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it
will host its second quarter 2023 investor update conference call
and webcast at 8:30 a.m. Eastern Time on Tuesday, August 8, 2023.
Individuals interested in participating in the call should dial
(888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international)
using conference ID number and event passcode 4671230. To access
the webcast, please visit the Investors section of Ironwood’s
website at www.ironwoodpharma.com at least 15 minutes prior to the
start of the call to ensure adequate time for any software
downloads that may be required.
The call will be available for replay via telephone starting
Tuesday, August 8, 2023 at approximately 11:30 a.m. Eastern Time,
running through 11:59 p.m. Eastern Time on Tuesday, August 22,
2023. To listen to the replay, dial (800) 770-2030 (U.S. and
Canada) or (647) 362-9199 (international) using conference ID
number 4671230. The archived webcast will be available on
Ironwood’s website for 14 days beginning approximately one hour
after the call has completed.
About Ironwood Pharmaceuticals Ironwood Pharmaceuticals
(Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading
global gastrointestinal (GI) healthcare company on a mission to
advance the treatment of GI diseases and redefine the standard of
care for GI patients. We are pioneers in the development of
LINZESS® (linaclotide), the U.S. branded prescription market leader
for adults with irritable bowel syndrome with constipation (IBS-C)
or chronic idiopathic constipation (CIC). LINZESS is also approved
for the treatment of functional constipation in pediatric patients
ages 6-17 years-old. Ironwood is also advancing apraglutide, a
next-generation, long-acting synthetic GLP-2 analog being developed
for rare gastrointestinal diseases, including short bowel syndrome
with intestinal failure (SBS-IF), as well as several earlier stage
assets. Building upon our history of GI innovation, we keep
patients at the heart of our R&D and commercialization efforts
to reduce the burden of GI diseases and address significant unmet
needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in
Boston, Massachusetts, and has operations in Basel,
Switzerland.
We routinely post information that may be important to investors
on our website at www.ironwoodpharma.com. In addition, follow us on
Twitter and on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230725055252/en/
Investors: Greg Martini, 617-374-5230
gmartini@ironwoodpharma.com
Matt Roache, 617-621-8395 mroache@ironwoodpharma.com
Media: Beth Calitri, 978-417-2031
bcalitri@ironwoodpharma.com
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Gráfica de Acción Histórica
De May 2023 a May 2024